SAN DIEGO, Feb. 10, 2016 -- Medical Marijuana, Inc. (OTC Pink:MJNA) is pleased to inform shareholders and the general public that the Company’s Chief Executive Officer, Dr. Stuart W. Titus, will deliver a historic keynote address on cannabidiol (CBD) at the VII Mexico City World Anti-Aging Congress on February 13th.
The global healthcare conference takes place February 12th – 14th at the Hotel Fiesta Americana Reforma, Mexico City. Last week, Mexico’s government (COFEPRIS) issued the first permits for individuals to begin importation of CBD hemp oil (RSHO-X™) with a doctor’s recommendation. This global healthcare education event represents the first opportunity for the medical community to receive hands-on education about CBD directly from the Chief Executive Officer of Medical Marijuana, Inc.
“We are extremely honored to participate in the VII Mexico City World Anti-Aging Congress to educate the healthcare community in Mexico about CBD,” says Stuart W. Titus, PhD and Chief Executive Officer of Medical Marijuana, Inc. “Our presentation will address the unique anti-aging properties of the hemp cannabis, research that supports cannabinoids as anti-oxidants and neuroprotectants, and why hemp is widely regarded as a ‘whole food’ and ‘superfood’ throughout the world.”
The VII Mexico City World Anti-aging Congress (Congreso Mundial en Medicina Antienvejecimiento AMA Mexico) event details are:
Congreso Mundial en Medicina Antienvejecimiento AMA Mexico
7th A4M Anti-Aging and Regenerative Medicine
Exhibit Space #19 – HempMeds® Mexico
12-14/02/2016
Puebla Privada Jalisco 8
Colonia El Carmen 7200
Tel: +56 80 65 68 or E-mail
www.medicina-antienvejecimiento.net
Venue: Hotel Fiesta Americana Reforma, Mexico City
For instructions on how to begin the RSHO-XTM import process, contact COFEPRIS for details. For information on RSHO-X™ product availability in Mexico, click here to register with HempMeds® Mexico website at http://www.hempmeds.mx. To speak with a HempMeds® Mexico representative, contact the customer service department at:
US: 1-866-786-2440
MX: 001-883-786-2440
Attention Members of the News Media:
Contact Andrew Hard to pre-register for a media pass to cover the historic keynote address and conduct interviews at the HempMeds® Mexico exhibit #19. Phone: 917.660.5418 or email to: [email protected]
About HempMeds® Mexico
HempMeds® Mexico is a Mexico-based company, created to provide access to cannabinoid-based products including cannabidiol (CBD) hemp oil products as they become legal in the country of Mexico for the first time. Our Company is a sales, marketing and distribution company. HempMeds® Mexico plans to work directly with the Mexican government to safely and legally provide access to our CBD hemp oil products. HempMeds® Mexico is the first company to legally ship RSHO-XTM CBD hemp oil into Mexico. For more information, please review the company’s website at: http://hempmeds.mx/.
About HempMeds®
HempMeds® offers mainstream marketing, sales, customer service, and logistics for the cannabis industry. HempMeds® is a corporate portfolio company of Medical Marijuana, Inc. (OTC Pink:MJNA) and the Company’s exclusive master distributor and contracted marketing company. In addition to handling sales and distribution, HempMeds® is the communication hub for the Medical Marijuana Inc. portfolio of companies.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
LEGAL DISCLOSURE
Medical Marijuana Inc. and HempMeds do not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
For further information, please contact: Public Relations contact: Andrew Hard Chief Executive Officer CMW Media P. 888-829-0070 [email protected] www.cmwmedia.com Corporate contact: Medical Marijuana, Inc. Toll Free: 888-OTC-MJNA (888-682-6562) www.medicalmarijuanainc.com www.facebook.com/mjnainc


Robinhood Expands Sports Event Contracts With Player Performance Wagers
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 



